These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 4625586)

  • 1. Oral and parenteral formulations of marijuana constituents.
    Rosenkrantz H; Thompson GR; Braude MC
    J Pharm Sci; 1972 Jul; 61(7):1106-12. PubMed ID: 4625586
    [No Abstract]   [Full Text] [Related]  

  • 2. An intravenous formulation of 9-tetrahydrocannabinol using a non-ionic surfactant.
    Cradock JC; Davignon JP; Litterst CL; Guarino AM
    J Pharm Pharmacol; 1973 Apr; 25(4):345. PubMed ID: 4146694
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys.
    Thompson GR; Rosenkrantz H; Schaeppi UH; Braude MC
    Toxicol Appl Pharmacol; 1973 Jul; 25(3):363-72. PubMed ID: 4199474
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral and intravenous toxicity of delta9-tetrahydrocannabinol in rhesus monkeys.
    Thompson GR; Fleischman RW; Rosenkrantz H; Braude MC
    Toxicol Appl Pharmacol; 1974 Mar; 27(3):648-65. PubMed ID: 4212215
    [No Abstract]   [Full Text] [Related]  

  • 5. Cannabinoid effects on liver glycogen stores.
    Sprague RA; Rosenkrantz H; Braude MC
    Life Sci II; 1973 May; 12(9):409-16. PubMed ID: 4633623
    [No Abstract]   [Full Text] [Related]  

  • 6. Preparation of 9-tetrahydrocannabinol for intravenous injection.
    Olsen JL; Makhani M; Davis KH; Wall ME
    J Pharm Pharmacol; 1973 Apr; 25(4):344. PubMed ID: 4146693
    [No Abstract]   [Full Text] [Related]  

  • 7. Distribution studies of (14C)delta-9-tetrahydrocannabinol in mice: effect of vehicle, route of administration, and duration of treatment.
    Mantilla-Plata B; Harbison RD
    Toxicol Appl Pharmacol; 1975 Nov; 34(2):292-300. PubMed ID: 1209626
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison among four vehicles and four routes for administering delta9-tetrahydrocannabinol.
    Sofia RD; Kubena RK; Barry H
    J Pharm Sci; 1974 Jun; 63(6):939-41. PubMed ID: 4851104
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of drug metabolism in drug research and development: pharmaceutical chemistry aspects.
    Heimlich KR
    J Pharm Sci; 1972 Oct; 61(10):1686-9. PubMed ID: 5072432
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhalation, parenteral and oral LD50 values of delta 9-tetrahydrocannabinol in Fischer rats.
    Rosenkrantz H; Heyman IA; Braude MC
    Toxicol Appl Pharmacol; 1974 Apr; 28(1):18-27. PubMed ID: 4852457
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of acute and chronic administration of marijuana extract on the rat electrocorticogram.
    Pirch JH; Cohn RA; Barnes PR; Barratt ES
    Neuropharmacology; 1972 Mar; 11(2):231-40. PubMed ID: 5025827
    [No Abstract]   [Full Text] [Related]  

  • 12. A study of teratological effects of intravenous, subcutaneous, and intragastric administration of delta9-tetrahydrocannabinol in mice.
    Joneja MG
    Toxicol Appl Pharmacol; 1976 Apr; 36(1):151-62. PubMed ID: 1273835
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hashish--chemistry and problems].
    Bieniek D; Gau W; Korte F
    Naturwissenschaften; 1974 Mar; 61(3):117-21. PubMed ID: 4826363
    [No Abstract]   [Full Text] [Related]  

  • 14. Physiochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol.
    Garrett ER; Hunt CA
    J Pharm Sci; 1974 Jul; 63(7):1056-64. PubMed ID: 4853640
    [No Abstract]   [Full Text] [Related]  

  • 15. Dosage form design of investigational drugs in cancer chemotherapy.
    Davignon JP
    Bull Parenter Drug Assoc; 1969; 23(2):83-9. PubMed ID: 4975731
    [No Abstract]   [Full Text] [Related]  

  • 16. The metabolism of the tetrahydrocannabinols.
    Lemberger L
    Adv Pharmacol Chemother; 1972; 10():221-55. PubMed ID: 4598605
    [No Abstract]   [Full Text] [Related]  

  • 17. Vehicle and route of administration as parameters affecting operant behavioral effects of 9 -tetrahydrocannabinol.
    Borgen LA; Davis WM
    J Pharm Sci; 1973 Mar; 62(3):479-80. PubMed ID: 4691712
    [No Abstract]   [Full Text] [Related]  

  • 18. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
    Agarwal V; Alayoubi A; Siddiqui A; Nazzal S
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1681-9. PubMed ID: 23072611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
    Cirri M; Mura P; Mora PC
    Int J Pharm; 2007 Aug; 340(1-2):84-91. PubMed ID: 17531411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Classification of chemical substance based on toxicity].
    Schmidt P; Unverricht S
    Z Arztl Fortbild (Jena); 1976 Jan; 70(2):53-9. PubMed ID: 822600
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.